Overt Hepatic Encephalopathy Market Size by Type, Application, Method, Region, Industry-Wide Analysis, Competitive Landscape Assessment & Long-Term Forecast to 2034
Overview
Overt Hepatic Encephalopathy Market was valued at USD 134.20 Mn in 2025. Global Overt Hepatic Encephalopathy Market size is expected to grow at a CAGR of 12.03 % through the forecast period.
Overt Hepatic Encephalopathy Market Overview:
Hepatic encephalopathy is a neurological disease, results in liver damage which alters the level of consciousness. Development chances get increased by approximately 55% of people who are suffering from cirrhosis during clinical care. Hepatic encephalopathy (HE) is part of a spectrum of neurocognitive changes in cirrhosis. HE is divided into two broad categories based on severity, covert (CHE) and overt (CHE). Overt Hepatic Encephalopathy is associated with increased rates of hospitalizations and mortality, and poor quality of life.
Overt Hepatic Encephalopathy Market Size, Growth & Share Analysis
To know about the Research Methodology :- Request Free Sample Report
Clinically, patients with OHE demonstrate global neurological deficits. In stages 2–3, motor system abnormalities are clinically apparent. These include hyper-reflexia, hypertonia, asterixis, bradykinesias, rigidity, tremors, and ataxia. Mentally (either behaviorally or cognitively), patients may be aggressive, agitated, disoriented to time and place, display bizarre behavior, have personality changes, have slurred speech, lethargic or apathetic. Overt HE is a particularly pressing problem. . Given the many targets of treatment and lack of a clear singular cause of overt HE, there is no consensus on a single best treatment. Over the past several years, high-quality studies have been conducted on the various pharmacologic therapies for HE and, as more data emerge, hopefully HE will become a much more easily treated complication of decompensated liver disease.
The report explores the Global market segments (Type, Application, Method and Region). Data has been provided by market participants, and regions (North America, Asia Pacific, Europe, Middle East & Africa, and South America). The MMR market report provides a thorough analysis of the rapid advances that are currently taking place across all industry sectors. Facts and figures, illustrations, and presentations are used to provide key data analysis for the historical period from 2020 to 2025. The report investigates the Global market drivers, limitations, prospects, and barriers. This MMR report includes investor recommendations based on a thorough examination of the Global Overt Hepatic Encephalopathy Market contemporary competitive scenario.
Overt Hepatic Encephalopathy Market Dynamics:
Drivers:
The rising number of people having cirrhosis disease is the major factor which leads to the growth of the global market. Cirrhosis is a chronic liver damage illness that can result in scarring and liver failure. Increasing consumption of alcohol has led to the increased incidence of liver disease among the people. This leads to the growth of the Global market. Growing emphasis on the development of advanced solutions by the market players resulted to driving the growth of the market during the forecast period.
Restrains:
High cost of rifaximin for the treatment of hepatic encephalopathy is the major factor which resulted into the restraining of the growth of the Global market. For instance, according to the National Centre for Biotechnology Information, hepatic encephalopathy is the second most common reason for hospitalization in patients suffering from liver cirrhosis, in the U.S., after ascites. The various research studies would propose long-term, probably life-long, rifaximin therapy for preventing hepatic encephalopathy recurrence, as liver cirrhosis is an irreversible disease. These all factors are expected to restrain the Global market during the forecast period.
COVID-19 Impact on Global Overt Hepatic Encephalopathy Market:
The COVID-19 pandemic is the one of the factors which limits the growth of the Global market. The financial status of businesses in all sectors are affected due to the coronavirus (COVID-19) pandemic which led to the imposing of lockdown in various countries across the globe. The private healthcare sector is one of the sectors, which has been majorly impacted by the pandemic. The lockdowns in various countries have created an economic burden on the private healthcare sector. Healthcare providers are facing challenges with regards to manpower, equipment, consumables, and other resources to ensure safety of patients with other diseases, and declining outpatient’s visits, among others. The pandemic has negatively impacted the development, production, and supply of drugs, and affected growth of the Global market.
Overt Hepatic Encephalopathy Market Segment Analysis:
Based on Type,The segment overt is expected to grow with the highest market share in year 2025. Due to the rise in the familiarity in liver diseases, the overt segment is expected to grow in global market. The factors such as the prevalence of cirrhosis, rising road accidental cases, increased healthcare expenditure, etc. are boosting the global overt hepatic encephalopathy market. As per the WHO report near about 30-40% of patients suffer from overt hepatic encephalopathy in the US.
Overt Hepatic Encephalopathy Market Regional Insights:
The North America region is expected to witness significant growth at a CAGR of xx% through the forecast period. The increase in the number of geriatric populations and increasing number of people suffering from cirrhosis lead to the growth of overt hepatic encephalopathy in North America region. Around 5.5 million people in the U.S are affected by cirrhosis and approximately 70% of them are likely to develop symptoms of overt hepatic encephalopathy. In addition, according to the data published in American Liver Foundation in 2020, hepatitis C infection caused by hepatitis C virus (HCV), is the leading cause of liver cirrhosis in the U.S., followed by alcohol consumption related cirrhosis, contributing to around 20% to 25% cases of liver cirrhosis. Furthermore, the Asia Pacific region projected to register a steady growth rate during the forecast period of (2026-2034) owing to the increasing rate of overt hepatic encephalopathy and increasing government initiative for healthcare reforms.
Europe is also expected to rise its market share in Global market during the forecast period. The increase in the research and development activities for the treatment and management of liver disease leads to the growth of the Global market in this region. Moreover, increase in the incidence of high overt hepatic encephalopathy owing to consumption of alcohol also boosting the growth of the market. ALIVER consortium developed a novel and innovative liver dialysis machine that will help the liver to naturally regenerate and to keep patients alive and healthy until a liver donor is available. The increasing prevalence of overt hepatic encephalopathy, increasing government support, and well-developed technology are the factors responsible for the rise in demand for the Global market during the forecast period.
The objective of the report is to present a comprehensive analysis of the Global market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.
PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.
The reports also help in understanding the Global Overt Hepatic Encephalopathy Market dynamic, structure by analyzing the market segments and projecting the Global Overt Hepatic Encephalopathy Market size. Clear representation of competitive analysis of key players by Vehicle type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Overt Hepatic Encephalopathy Market make the report investor’s guide.
Overt Hepatic Encephalopathy Market Recent Development:
| Date | Company | Development | Impact |
|---|---|---|---|
| 15 January 2025 | Bausch Health Companies Inc. | Bausch Health announced the expansion of its manufacturing facility dedicated to producing XIFAXAN® (rifaximin) to meet growing global demand. | The expanded production capacity significantly increases the global supply of the leading standard-of-care therapy for reducing the recurrence of overt hepatic encephalopathy. |
| 18 April 2025 | Mallinckrodt plc | Mallinckrodt entered into a strategic collaboration with a leading GI clinical network to advance late-stage clinical trial protocols for novel target therapeutics aimed at acute OHE exacerbations. | The partnership accelerates the development timeline for targeted therapies designed to rapidly decrease systemic ammonia concentrations in hospitalized patients. |
| 22 September 2025 | Axcella Health Inc. | Axcella Health received positive regulatory feedback and protocol alignment from European regulatory authorities for its Phase 2b clinical trial evaluating amino acid compositions for OHE management. | This milestone paves the way for streamlined multi-center clinical evaluation across European hospital networks, expanding international development pipelines. |
| 12 November 2025 | Lupin Pharmaceuticals | Lupin received final regulatory approval for its generic version of lactulose oral solution for the prevention and treatment of hepatic encephalopathy. | The approval enhances market competition and improves affordable patient access to first-line osmotic laxative therapies across key emerging markets. |
| 10 February 2026 | Horizon Therapeutics | Horizon Therapeutics acquired a specialized gastroenterology biotech portfolio focused on non-absorbable gut-selective ammonia scavengers. | The acquisition strengthens Horizon’s rare liver disease segment and expands its R&D pipeline targeting severe overt hepatic encephalopathy complications. |
Global Overt Hepatic Encephalopathy Market Scope: Inquire before buying
| Overt Hepatic Encephalopathy Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2034 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | USD 134.20 Mn. |
| Forecast Period 2026 to 2034 CAGR: | 12.03% | Market Size in 2034: | USD 373.05 Mn. |
| Segments Covered: | by Type | Overt Covert |
|
| by Application | Hospitals Clinics Medical Research Institutes |
||
| by Method | Drug Treatment Lactulose Pathophysiology Prognosis Liver transplantation |
||
Overt Hepatic Encephalopathy Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina, Columbia and Rest of South America)
Overt Hepatic Encephalopathy Market Key Players are
1.Alfa Wassermann
2. Cosmo Pharmaceuticals
3. Horizon Pharma
4. KannaLife Sciences
5. Ocer Therapeutics
6. Spherium Biomed
7. ASKA Pharmaceutical
8. Valeant
9. Mallinckrodt
10. Umecrine Cognition
11. Rebiotix
12. Norgine B.V.
13. Lupin Limited
14. Kaleido Biosciences
15. Bausch Health Companies Inc.
16. Ferring Pharmaceuticals Inc.
Frequently Asked Questions:
1] What segments are covered in the Global Overt Hepatic Encephalopathy Market report?
Ans. The segments covered in the Global Overt Hepatic Encephalopathy Market report are based on Type, Application and Method.
2] Which region is expected to hold the highest share in the Global Overt Hepatic Encephalopathy Market?
Ans. North America region is expected to hold the highest share in the Global Overt Hepatic Encephalopathy Market.
3] What is the market size of the Global Overt Hepatic Encephalopathy Market by 2034?
Ans. The market size of the Global Overt Hepatic Encephalopathy Market by 2034 is expected to reach USD 373.05 Mn.
4] What is the forecast period for the Global Overt Hepatic Encephalopathy Market?
Ans. The forecast period for the Global Overt Hepatic Encephalopathy Market is 2026-2034.
5] What was the market size of the Global Overt Hepatic Encephalopathy Market in 2025?
Ans. The market size of the Global Overt Hepatic Encephalopathy Market in 2025 was valued at USD 134.20 Mn.